Rifampin-resistant meningococcal infection in a patient given rifampin chemoprophylaxis

Berkey, Peter; Rolston, Kenneth; Zukiwski, Alex; Gooch, Grace; Bodey, Gerald P.

doi:10.1016/s0196-6553(88)80004-x

Cited by 9 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase may have been due to recolonization following discontinuation of prophylaxis (85). Resistance of N. meningitidis following prophylaxis has been documented both in patients who were only colonized and in those who developed invasive disease following rifampin prophylaxis (8,21,51).…”

Section: Gram-negative Coccimentioning

confidence: 99%

Use of rifampin in nonstaphylococcal, nonmycobacterial disease

Morris

Brown

Sands

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Rifampin has very broad antimicrobial properties with in vitro activities against many bacteria, mycobacteria, higher bacteria, chlamydia, fungi, parasites, and viruses (Table 1). The clinical use of rifampin is more limited, in part because of the lack of in vivo human clinical studies demonstrating its efficacy. Investigators have valid concerns regarding the emergence of resistance of mycobacteria if widespread use of rifampin becomes common, although this has not been well documented. Because rifampin obtains therapeutic levels intracellularly and is distributed widely throughout the body, the antibiotic potentially could be used on a broader scale, but more studies will be needed to demonstrate its clinical utility.

show abstract

Section: Gram-negative Coccimentioning

confidence: 99%

Use of rifampin in nonstaphylococcal, nonmycobacterial disease

Morris

Brown

Sands

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Rifampin resistance occurs in several bacteria, including Staphylococcus aureus [24], Neisseria meningitidis [25], Mycobacterium tuberculosis [26], Escherichia coli [27,28], and Streptococcus pneumoniae [29]. In addition, a few pathogenic species of spotted fever group Rickettsia, including Rickettsia massiliae and Rickettsia aeschlimannii, are resistant to rifampin in vitro [16,30], and therapeutic failures have been reported when rifampin is used as primary therapy for rickettsial infections in regions where R. massiliae is prevalent [31,32].…”

Section: Discussionmentioning

confidence: 99%